Online citations, reference lists, and bibliographies.
← Back to Search

Quantifying Effect Of Statins On Low Density Lipoprotein Cholesterol, Ischaemic Heart Disease, And Stroke: Systematic Review And Meta-analysis

M. Law, N. Wald, A. Rudnicka
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Objectives To determine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (IHD) events and stroke, according to drug, dose, and duration of treatment. Design Three meta-analyses: 164 short term randomised placebo controlled trials of six statins and LDL cholesterol reduction; 58 randomised trials of cholesterol lowering by any means and IHD events; and nine cohort studies and the same 58 trials on stoke. Main outcome measures Reductions in LDL cholesterol according to statin and dose; reduction in IHD events and stroke for a specified reduction in LDL cholesterol. Results Reductions in LDL cholesterol (in the 164 trials) were 2.8 mmol/l (60%) with rosuvastatin 80 mg/day, 2.6 mmol/l (55%) with atorvastatin 80 mg/day, 1.8 mmol/l (40%) with atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, or rosuvastatin 5 mg/day, all from pretreatment concentrations of 4.8 mmol/l. Pravastatin and fluvastatin achieved smaller reductions. In the 58 trials, for an LDL cholesterol reduction of 1.0 mmol/l the risk of IHD events was reduced by 11% in the first year of treatment, 24% in the second year, 33% in years three to five, and by 36% thereafter (P < 0.001 for trend). IHD events were reduced by 20%, 31%, and 51% in trials grouped by LDL cholesterol reduction (means 0.5 mmol/l, 1.0 mmol/l, and 1.6 mmol/l) after results from first two years of treatment were excluded (P < 0.001 for trend). After several years a reduction of 1.8 mmol/l would reduce IHD events by an estimated 61%. Results from the same 58 trials, corroborated by results from the nine cohort studies, show that lowering LDL cholesterol decreases all stroke by 10% for a 1 mmol/l reduction and 17% for a 1.8 mmol/l reduction. Estimates allow for the fact that trials tended to recruit people with vascular disease, among whom the effect of LDL cholesterol reduction on stroke is greater because of their higher risk of thromboembolic stroke (rather than haemorrhagic stroke) compared with people in the general population. Conclusions Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17%.
This paper references
10.1161/01.CIR.97.10.946
Cholesterol reduction yields clinical benefit: impact of statin trials.
A. L. Gould (1998)
10.7326/0003-4819-125-12-199612150-00011
Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment
G. Schectman (1996)
A meta - analysis of randomised , placebo controlled , double - blind trials with HMG - CoA reductase inhibitors
GJ Blauw (1997)
10.1097/00132586-200012000-00024
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
J. Larosa (2000)
10.1161/01.STR.28.5.946
Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors.
G. J. Blauw (1997)
10.1136/bmj.308.6925.367
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
M. Law (1994)
10.1136/bmj.326.7404.1427
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
M. Law (2003)
10.1001/JAMA.1990.03440160047035
Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988.
D. Wysowski (1990)
10.1016/S0002-9149(97)00965-X
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
P. Jones (1998)
10.1016/S0140-6736(95)92836-7
Cholesterol, diastolic blood pressure and stroke: 13.000 strokes in 450.000 people in 45 prospective cohorts.
D. Kromhout (1995)
10.7326/0003-4819-128-2-199801150-00002
Effect of HMGcoA Reductase Inhibitors on Stroke
H. Bucher (1998)
10.1136/bmj.308.6925.373
Assessing possible hazards of reducing serum cholesterol
M. Law (1994)
10.1136/bmj.319.7224.1562
When can a risk factor be used as a worthwhile screening test?
N. Wald (1999)
10.1136/bmj.308.6925.363
Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study
M. Law (1994)
10.1016/S0021-9150(98)00014-8
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.
J. Crouse (1998)
10.1016/S0140-6736(95)92836-7
Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts
Prospective Studies Collaboration (1995)
10.1161/01.CIR.91.8.2274
Cholesterol reduction yields clinical benefit. A new look at old data.
A. L. Gould (1995)
10.1002/j.1552-4604.1996.tb04224.x
Pharmacodynamic Effects and Pharmacokinetics of Atorvastatin after Administration to Normocholesterolemic Subjects in the Morning and Evening
D. Cilla (1996)
Cholesterol reduction yields clinical benefit
A L Gould (1998)
10.1161/01.STR.28.3.491
Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration.
C. Sudlow (1997)
10.1191/1358863X03VM518XX
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003; 326: 1407-408.
Sonia S Anand (2003)
10.1136/bmj.325.7374.1202
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
D. Wald (2002)
10.1056/NEJM200202143460721
Cerivastatin and reports of fatal rhabdomyolysis.
J. Staffa (2002)
10.1002/CLC.4960230108
Lipid‐Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long‐Term Experience in a Large Group of Patients with Hypercholesterolemia
L. Ose (2000)
Prescribed use of cholesterollowering drugs in the United States
D K Wysowski (1978)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1097/00132586-199806000-00060
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
P. Hebert (1997)
10.1001/ARCHINTE.162.21.2405
The underlying risk of death after myocardial infarction in the absence of treatment.
M. Law (2002)
10.1136/bmj.321.7267.983
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
M. Pignone (2000)



This paper is referenced by
10.1016/B978-2-294-71346-0.50039-2
Chapitre 39 - Pharmacologie et Thérapeutique Vasculaire
Société française de médecine vasculaire (2011)
Original article Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study
E. Heintjes (2009)
10.1055/s-0035-1545991
[Factors with Impact on the Outcome after Surgical Interventions for Abdominal Aortic Aneurysms].
Jennifer Bardenhagen (2015)
10.4155/CLI.12.127
Polypill (fixed-dose combination) in the prevention of cardiovascular disease: rationale and clinical data
K. Singh (2012)
Cholesterol as a Risk Factor for Stroke The Fugitive ?
G. Donnan (2004)
Which lifestyle interventions effectively lower LDL cholesterol ?
CliniCal INquIrIes (2007)
Effectiveness and safety of a cardiovascular polypill containing aspirin
Vanessa Selak (2015)
Caractérisation des profils de traitements pour accident vasculaire cérébral et événements cliniques associés
Mareva Faure (2018)
10.21518/2079-701X-2019-16-21-26
Фиксированная комбинация «розувастатин + эзетимиб» – удобство, безопасность и эффективность
Ирина Александровна Алексеева (2019)
10.1517/13543784.13.8.987
Novel antihypertensive agents
Cristina Sierra (2004)
10.2139/ssrn.1782055
The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs
Andrew T. Ching (2015)
10.1136/bmjopen-2017-015935
Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening
N. Ooba (2017)
10.1161/ATVBAHA.107.145151
A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia
H. Avis (2007)
10.1016/J.NUMECD.2007.05.009
Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment.
M. Takeshita (2008)
10.1016/S0828-282X(07)70786-9
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
S. Grover (2007)
Screening for and Management of Obesity and Overweight in Adults
E. LeBlanc (2011)
10.1007/s00228-011-1037-0
Suboptimal use of statins at treatment initiation
V. Kiviniemi (2011)
10.3310/hta13340
Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
R. Ara (2009)
10.1016/j.atherosclerosis.2009.12.023
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.
E. Bruckert (2010)
10.1016/J.LPM.2007.07.016
Morbidité et mortalité à 10 ans d’une cohorte de patients dyslipidémiques ayant consulté en centre hospitalier
V. Carreau (2008)
10.1016/S0140-6736(08)60516-4
Cholesterol, statins, and mortality
M. Law (2008)
10.1556/OH.2008.28267
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
L. Szapáry (2008)
10.4068/CMJ.2008.44.1.13
Statin Reduces C-Reactive Protein and Interleukin-6 in Normocholesterolemic Patients with Acute Coronary Syndrome
O. Park (2008)
A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer
M. E. Irwin (2010)
10.1016/j.transci.2009.05.013
26 years of LDL--apheresis: a review of experience.
H. Borberg (2009)
CLINICAL CONCEPTS AND COMMENTARY
Y. L. Manach (2004)
10.1055/S-0042-121868
Atorvastatin-Therapie in der Praxis – LDL-Werte bei Patienten mit sehr hohem kardiovaskulären Risiko
U. Laufs (2017)
10.1007/s00228-005-0980-z
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease
S. Perreault (2005)
10.1159/000083386
Lowering LDL Cholesterol: Where Is the End of the Journey?
W. März (2005)
10.1002/MNFR.200500081
Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin.
D. Steinberg (2005)
10.1016/J.APRIM.2009.04.008
Opciones terapéuticas farmacológicas de la dislipemia
Antonio Maiques Galán (2010)
NON-STANDARD DRUGS REQUESTS REVIEWS: ROLE OF PHARMACIST AT RESEARCH AND DRUG INFORMATION UNIT (RDIU), HOSPITAL UNIVERSITI SAINS MALAYSIA (HUSM)
Z. Zahari (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar